Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs

Aims: This study evaluated the cost-effectiveness of telotristat ethyl (TE) added to somatostatin analog octreotide (SSA + TE) compared to octreotide alone (SSA) in patients with carcinoid syndrome diarrhea (CSD) whose symptoms remain uncontrolled with SSA alone. Materials and methods: A determinist...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of medical economics 2018-02, Vol.21 (2), p.182-188
Hauptverfasser:	Joish, V. N., Frech, F., Lapuerta, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Carcinoid syndrome cost-effectiveness diarrhea neuroendocrine tumors somatostatin analogs telotristat ethyl
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!